BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

A VC syndicate that backed IFM and serial dealmaker Gary Glick has launched precision oncology start-up Scorpion, where Glick will be president and CEO, with $108 million in series A funding. Scorpion...
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the...
BioCentury | Oct 17, 2020
Finance

Novartis Venture Fund’s move to earlier, riskier bets starting to pay off

Over the last three and a half years, Novartis Venture Fund has remade its team and narrowed its remit to early-stage opportunities in therapeutics. The fund’s 2020 exits suggest the strategic shift may...
BioCentury | Oct 7, 2020
Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

Roche’s deal to acquire a clinical cystic fibrosis program from U.K.-based Enterprise delivers a return to the biotech’s shareholders while allowing the venture-backed company to continue development of another pipeline project. Roche (SIX:ROG; OTCQX:RHHBY) is...
BioCentury | Jul 30, 2020
Deals

F-Star lands on NASDAQ sooner than expected via reverse merger

At the year’s start F-Star Therapeutics’ plan was to ride out the expected volatility of the U.S. election year and seek a public listing in 2021. That changed when Spring Bank called with an opportunity...
BioCentury | Jul 29, 2020
Finance

Enthera’s €28M series A latest sign of growth for Italy’s biotech ecosystem

U.S. and European investors are backing the largest-ever series A financing for an Italian biotech, autoimmune play Enthera s.r.l. Enthera raised €28 million ($32.8 million) in the round, which was led by existing investor Sofinnova...
BioCentury | Jun 26, 2020
Distillery Therapeutics

Blocking cGAS for colitis

DISEASE CATEGORY: Gastrointestinal INDICATION: Colitis Colitis may be treatable by targeting cGAS, a cytosolic DNA sensor that triggers inflammatory signaling through STING activity. In a mouse model of chemically induced colitis, systemic GSDMD knockout exacerbated...
BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

By uniting with publicly traded Aduro, Versant Ventures-incubated kidney company Chinook will gain a clinical asset for IgA nephropathy while also delivering liquidity to a VC syndicate that is committing additional capital to fund the...
BioCentury | May 30, 2020
Finance

Ovarian cancer data help Mersana raise $152M to top off $9B month of follow-ons

Catalyzed by interim data unveiled Wednesday from a Phase I trial of its lead product, Mersana raised $152 million late Thursday to advance its clinical and preclinical antibody-drug conjugates. Mersana Therapeutics Inc. (NASDAQ:MRSN), which also...
BioCentury | May 29, 2020
Product Development

Minerva’s schizophrenia miss casts doubt on approach to treating negative symptoms

Minerva’s Phase III miss in schizophrenia sent its shares down 72% on Friday, putting into doubt the future of the leading therapeutic candidate in development to treat the negative symptoms of schizophrenia -- an indication...
Items per page:
1 - 10 of 136